Katherine Sanchez, MD
Medical Oncology · Albuquerque, NMNPI 1558740647
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,245 of the $26,392 with a category attached, or 61.6%. 31 manufacturers reported payments, led by AstraZeneca at 30.1% of the total.
Across 118 payments — averaging $223.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$8K
- Lilly USA, LLC$6K
- Eli Lilly$6K
- Pfizer$1K
- Stemline Therapeutics Inc.$1K
- Daiichi Sankyo Inc.$958
- plus $3K from 25 others
Across 14 payments — averaging $44,920 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$327K
- Merck$158K
- Eli Lilly$143K
- E.r. Squibb & Sons, L.L.C.$1K
What the payments were for
- Consulting fees$16,24562%
- Speaking & faculty fees$2,2158%
- Travel & lodging$2,2288%
- Food & beverage$5,46521%
- Education$2391%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 33 | $7,944 |
| Lilly USA, LLC | 11 | $5,879 |
| Eli Lilly | 9 | $5,736 |
| Pfizer | 4 | $1,349 |
| Stemline Therapeutics Inc. | 6 | $1,324 |
| Daiichi Sankyo Inc. | 4 | $958 |
| E.r. Squibb & Sons, L.L.C. | 4 | $939 |
| Genentech USA, Inc. | 4 | $337 |
| Gilead | 4 | $281 |
| Bayer | 4 | $158 |
| Johnson & Johnson(2 entities) | 2 | $152 |
| Novartis | 3 | $147 |
| Bristol Myers Squibb | 7 | $138 |
| Astrazeneca UK Limited | 1 | $135 |
| Boston Scientific | 1 | $129 |
| Sanofi | 1 | $118 |
| Rigel Pharmaceuticals, Inc. | 1 | $111 |
| ASD Specialty Healthcare, LLC | 1 | $88 |
| Seagen Inc. | 1 | $85 |
| Regeneron Healthcare Solutions, Inc. | 2 | $71 |
| Genentech, Inc. | 1 | $54 |
| Merck | 3 | $53 |
| Eisai Inc. | 2 | $45 |
| Amgen | 2 | $44 |
| Beigene USA, Inc. | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Incyte Corporation | 1 | $19 |
| Agios Pharmaceuticals, Inc. | 1 | $15 |
| Pharmaessentia USA Corporation | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Sobi, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few medical oncology providers in New Mexicoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 26 | $357,007 |
| BrukinsaZanubrutinib | 21 | $248,144 |
| TagrissoOsimertinib Mesylate | 14 | $220,548 |
| VerzenioAbemaciclib | 13 | $196,255 |
| EliquisApixaban | 20 | $14,448 |
| XareltoRivaroxaban | 22 | $11,741 |
| Exemestane | 39 | $9,876 |
| Imatinib Mesylate | 18 | $9,070 |
| Letrozole | 278 | $6,869 |
| Abiraterone Acetate | 12 | $1,563 |
| Tamoxifen Citrate | 40 | $1,128 |
| Anastrozole | 43 | $1,089 |
| Ondansetron OdtOndansetron | 26 | $553 |
| Dexamethasone | 17 | $546 |
| Prochlorperazine Maleate | 30 | $472 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali | $147 | $357,00726 claims |
| Beigene USA, Inc.Brukinsa | $20 | $248,14421 claims |
| AstraZenecaTagrisso | $7,944 | $220,54814 claims |
| Lilly USA, LLCVerzenio | $5,879 | $196,25513 claims |
| PfizerEliquis | $1,349 | $14,44820 claims |
| Johnson & JohnsonXarelto | $152 | $11,74122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in New Mexicoon file to place this against a meaningful peer group, so we don't.
Other medical oncology in Albuquerque
- Annette FontaineAlbuquerque$208K
- Atul KumarAlbuquerque$9K
- Sofia Palacio CardenasAlbuquerque$5K
- Malcolm PurdyAlbuquerque$3K
- Amyn AlidinaAlbuquerque$2K
- Ronald KubicaAlbuquerque$1K
- Joseph EkofoAlbuquerque$195
- Colbert ParkerAlbuquerque$103
- Richard GiudiceAlbuquerque$0
- Wadih ArapAlbuquerque$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.